Global Retirement Partners LLC Makes New Investment in United Therapeutics Corporation $UTHR

Global Retirement Partners LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, Holdings Channel.com reports. The firm acquired 1,509 shares of the biotechnology company’s stock, valued at approximately $817,000.

Other large investors have also recently added to or reduced their stakes in the company. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 1.9%

Shares of United Therapeutics stock opened at $518.27 on Wednesday. The business has a 50-day moving average price of $534.53 and a two-hundred day moving average price of $536.74. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The company has a market cap of $22.23 billion, a P/E ratio of 18.54, a PEG ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the company posted $6.41 earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on UTHR. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Bank of America cut their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $506.59, for a total value of $4,812,605.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $164,359,579.37. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 452,575 shares of company stock valued at $245,684,184 in the last three months. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.